サイクロオキシゲネーゼ-2は,LDL受容体欠乏マウスの早期動脈硬化病変形成を促進する
Michael E Burleigh1, Vladimir R Babaev, John A Oates
1Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tenn, USA.
Circulation
|April 17, 2002
まとめ
選択的サイクロオキシゲナーゼ-2 (COX-2) 阻害は,マウスの早期動脈硬化症を減少させます. マクロファージのCOX-2発現は,動脈硬化症の発達にも寄与し,抗炎症戦略をサポートします.
科学分野:
- 心血管研究 循環器科の研究
- 炎症と免疫学について
- 薬理学 薬理学とは
背景:
- 動脈硬化症は炎症によって特徴付けられます.
- サイクロオキシゲナーゼ-2 (COX-2) は,動脈硬化性損傷に存在し,炎症を促進します.
研究 の 目的:
- 選択的なCOX-2阻害がLDL受容体欠乏性 (LDLR-/-) のマウスにおける早期の病変形成を減少させるかどうかを調査する.
- マクロファージのCOX-2発現が,LDLR-/-マウスにおけるアテロゲネシスに寄与するかどうかを判断する.
主な方法:
- 雄性LDLR-/-マウスは,ロフェコキシブまたはインドメタチン (選択的COX-2阻害剤) で治療されたか,胎児の肝臓細胞移植を受け,マクロファージの欠乏したマウスCOX-2を生成しました.
- ネズミは6~8週間,欧米の食生活で餌を与えられた.
- 動脈硬化症は大動脈で評価され,血清脂質が測定されました.
主要な成果:
- ロフェコキシブとインドメタシンによる治療は,大動脈動脈硬化症を著しく減少させた.
- マクロファージのCOX-2発現 (COX-2-/- --> LDLR-/-) が欠けていたマウスは,対照群と比較して動脈硬化症が著しく減少した.
- ロフェコキシブは血小板血栓素の産生に影響を及ぼさなかったが,尿中のプロスタサイクリンの代謝産物濃度を低下させた.
- 血清脂質レベルは,両方の研究でグループ間で有意に異なっていなかった.
結論:
- 薬理学的および遺伝学的証拠は,COX-2がLDLR-/-マウスの早期動脈硬化性病変形成を促進することを示しています.
- これらの発見は,動脈硬化症の予防のための抗炎症的アプローチの可能性を支持しています.
関連する概念動画
Inflammation
Overview
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid Catabolism
Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...


